|
|
| | ML604086 Basic information |
| Product Name: | ML604086 | | Synonyms: | ML604086;Benzamide, N-[4-[[[(3R,4R)-1-[(2S)-2-amino-1-oxopropyl]-3-methyl-4-piperidinyl]amino]sulfonyl]-1-naphthalenyl]-2-methyl-;chemotaxis,inhibit,Inhibitor,ML-604086,ML604086,pro-inflammatory cytokine,CCR,ML 604086,CC chemokine receptor,T-cells,asthma;N-(4-(N-((3R,4R)-1-(L-Alanyl)-3-methylpiperidin-4-yl)sulfamoyl)naphthalen-1-yl)-2-methylbenzamide;ML604086, 10 mM in DMSO | | CAS: | 850330-18-6 | | MF: | C27H32N4O4S | | MW: | 508.63 | | EINECS: | | | Product Categories: | | | Mol File: | 850330-18-6.mol |  |
| | ML604086 Chemical Properties |
| form | Solid | | color | White to off-white |
| | ML604086 Usage And Synthesis |
| Description | ML604086 is a selective inhibitor of schemokine receptor CCR8. | | Uses | ML604086 is a selective CCR8 inhibitor, inhibiting CCL1 binding to CCR8 on circulating T-cells. ML604086 inhibits CCL1 mediated chemotaxis and increases in intracellular Ca2+ concentrations[1][2]. | | in vivo | ML604086 (1.038 mg/kg; intravenous infusion) shows no effect on airway eosinophilia, pro-inflammatory cytokine production or airway resistance and compliance in Macaca fascicularis[1]. | Animal Model: | 3.0-5.0 kg male and female adult Macaca fascicularis (primate model
of asthma)[2] | | Dosage: | 1.038 mg/kg | | Administration: | Intravenous infusion | | Result: | Did not effected the Changes in airway resistance and compliance induced by allergen provocation and increasing concentrations of methacholine. |
| | IC 50 | CCR8 | | References | [1] James E. Pease, et al. Chemokine Receptors in Allergy, Inflammation, and Infectious Disease. Top Med Chem (2015) 14: 1-40.
[2] Lin Wang, et al. Antagonism of chemokine receptor CCR8 is ineffective in a primate model of asthma. Thorax 2013;68:506–512. |
| | ML604086 Preparation Products And Raw materials |
|